Possible contribution of aprepitant to ifosfamide-induced neurotoxicity

American Journal of Health-System Pharmacy

Volumn 65, Issue 23, 2008, Pages 2229-2231

  Jarkowski III, Anthony ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antiemetics; Antineoplastic agents; Aprepitant; Carboplatin; Dexamethasone; Drug interactions; Enzyme inhibitors; Etoposide; Ifosfamide; Methylene blue; Ondansetron; Toxicity

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CORTICOSTEROID; CYTOCHROME P450 3A4; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHYLENE BLUE; ONDANSETRON; PALONOSETRON; SEROTONIN ANTAGONIST;

ADD ON THERAPY; ADULT; ARTICLE; AUDITORY HALLUCINATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; COMBINATION CHEMOTHERAPY; CONFUSION; DELIRIUM; DROWSINESS; DRUG METABOLISM; DRUG SUBSTITUTION; ENZYME INDUCTION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NERVE SHEATH TUMOR; NEUROTOXICITY; PRIORITY JOURNAL; RATING SCALE; TREATMENT RESPONSE; TUMOR RECURRENCE; VISUAL HALLUCINATION;

EID: 57149109164     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080069     Document Type: Article

References (13)

1. Emend (aprepitant) package insert. West Point, PA: Merck and Co.; 2006.
2. Kesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol. 2003; 21:4112-9.
3. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003; 97:3090-8.
4. Zhang J, Tian Q, Zhou S. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther. 2006; 1:55-84.
5. Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006; 40:299-303.
6. Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004; 44:215-23.
7. Majumdar AK, Yan KX, Selverian DV et al. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol. 2007; 47:744-50.
8. Majumdar AK, McCrea JB, Panebianco DL et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003; 74:150-6.
9. De Jonge ME, Huitema AD, Holtkamp MJ et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005; 56:370-8.
10. McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003; 74:17-24.
11. Durand JP, Gourmel B, Mir O et al. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol. 2007; 18:808-9. Letter.
12. Bruggemann SK, Pfaffle S, Peters SO et al. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab Dispos. 2007; 35:1721-4.
13. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:230-45.